Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immatics (IMTX)
NASDAQ:IMTX
Holding IMTX?
Track your performance easily
IMTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.98 - $13.77
Previous Close$9.25
Volume646.62K
Average Volume (3M)500.06K
Market Cap
$1.10B
Enterprise Value$657.52M
Total Cash (Recent Filing)€425.89M
Total Debt (Recent Filing)€15.40M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 12, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding103,110,000
10 Day Avg. Volume315,354
30 Day Avg. Volume500,063
Standard Deviation0.14
R-Squared0.11
Alpha-0.00614
Financial Highlights & Ratios
Price to Book (P/B)4.24
Price to Sales (P/S)15.85
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$17.50Price Target Upside89.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Immatics News
PremiumCompany Announcements
Immatics Unveils Promising TCR-T Therapy Developments
PremiumCompany Announcements
Immatics N.V. Announces Major Share Offering
PremiumCompany Announcements
Immatics Advances IMA203 to Phase 3 Trial in Melanoma
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe updated efficacy data for IMA203 is very impressive, especially considering a heavily pre-treated advanced patient population.
Market PositionIMTX is viewed as a leader in TCR therapeutics and attractively valued with a broad platform encompassing both TCR T-cell therapy and TCR bispecifics.
Strategic DevelopmentsIMTX will advance IMA203 into a registrational P3 trial following positive FDA feedback.
Bears Say
Clinical Trial ResultsThe updated 46% overall response rate for IMA203CD8 was slightly lower than the previously reported 56%.
Data TransparencyMany key details for the updated IMA203CD8 data were lacking in the abstract.
Equity FinancingIMTX shares dropped 16%, suspected to be related to the surprising decision to announce an equity financing.
---
Ownership Overview
―
Insiders
11.22% Mutual Funds
0.19% Other Institutional Investors
88.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $7.98 and its highest was $13.77 in the past 12 months.
What is Immatics’s market cap?
Currently, no data Available
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is Nov 12, 2024 which is in 3 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on Aug 13, 2024. The company reported -$0.185 earnings per share for the quarter, beating the consensus estimate of -$0.307 by $0.122.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -$0.27.
How many shares outstanding does Immatics have?
Immatics has 119,355,900 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -$0.185 in its last earnings report, beating expectations of -$0.307. Following the earnings report the stock price went up 1.231%.
Which hedge fund is a major shareholder of Immatics?
Among the largest hedge funds holding Immatics’s share is Perceptive Advisors LLC. It holds Immatics’s shares valued at 94M.
---
Immatics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.50 (89.19% Upside)
$17.50 (89.19% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.03%
12-Months-Change
Fundamentals
Return on Equity
-24.37%
Trailing 12-Months
Asset Growth
50.15%
Trailing 12-Months
Company Description
Immatics
Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
---
IMTX Stock 12 Month Forecast
Average Price Target
$17.50
▲(89.19% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Atara Biotherapeutics
―
Fate Therapeutics
―
Meiragtx Holdings
―
Best Analysts Covering IMTX
1 Year
1 Year Success Rate
6/19 ratings generated profit
1 Year Average Return
-1.17%
reiterated a buy rating 12 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 31.58% of your transactions generating a profit, with an average return of -1.17% per trade.
---